188Re-HDD/lipiodol therapy for hepatocellular carcinoma: A phase I clinical trial

Journal of Nuclear Medicine

Volumn 46, Issue 1, 2005, Pages 60-66

  Lambert, Bieke ^a   Bacher, Klaus ^b   Defreyne, Luc ^a   Gemmel, Filip ^a   Van Vlierberghe, Hans ^a   Jeong, Jae Min ^c   Dierckx, Rudi A ^a   Van De Wiele, Christophe ^a   Thierens, Hubert ^b   De Vos, Filip ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

4 hexadecyl 1,2,9,9 tetramethyl 4,7 diaza 1,10 decanethiol; 188Re; Hepatocellular carcinoma; Lipiodol; Radionuclide therapy

Indexed keywords

ALPHA FETOPROTEIN; IODINATED POPPYSEED OIL; 188RE 4 HEXADECYL 1,2,9,9 TETRAMETHYL 4,7 DIAZA 1,10 DECANETHIOL LIPIODOL CONJUGATE; 188RE-4-HEXADECYL-1,2,9,9-TETRAMETHYL-4,7-DIAZA-1,10-DECANETHIOL LIPIODOL CONJUGATE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COUGHING; DOSIMETRY; DYSPNEA; FEMALE; GAMMA SCINTIGRAPHY; HALF LIFE TIME; HUMAN; HYPERBILIRUBINEMIA; KIDNEY CLEARANCE; LIVER CELL CARCINOMA; LIVER TOXICITY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PLASMA CLEARANCE; PRIORITY JOURNAL; URINALYSIS; VENOUS BLOOD; ANTIBODY SPECIFICITY; CLINICAL TRIAL; LIVER TUMOR; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; TISSUE DISTRIBUTION;

AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IODIZED OIL; LIVER NEOPLASMS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; ORGAN SPECIFICITY; ORGANOMETALLIC COMPOUNDS; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 15044358105     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Parkin MD. Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: globocan 2000. Int J Cancer. 2001;94:153-156.
2. El-Serag HB, Masson AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750.
3. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United Stales: an update. Ann Intern Med. 2003;139:817-823.
4. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet. 1999;353:1253-1257.
5. Giovannini M, Elias D, Monges G, Raoul JL, Rougier P. Hepatocellular carcinoma. Br J Cancer. 2001;84:74-77.
6. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429-442.
7. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362: 1907-1917.
8. Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131-1-iodized oil in the treatment of hepatocellular carcinoma. Hepatology. 1997;26:1156-1161.
9. Leung WT, Lau WY, Ho S, et al. Selective internal radiation therapy with intra-arterial iodine-131-lipiodol in inoperable hepatocellular carcinoma. J Nucl Med. 1994;35:1313-1318.
10. 131I-lipiodol. Cancer Biother Radiopharm. 2000;15:65-70.
11. Knapp FF. Rhenium-188: a generator-derived radioisotope for cancer therapy. Cancer Biother Radiopharm. 1998;13:337-349.
12. Wang SJ, Lin WY, Chen MN, et al. Biodistribution of rhenium-188 lipiodol infused via the hepatic artery of rats with hepatic tumours. Eur J Nucl Med. 1996;23:13-17.
13. Jeong JM, Kim YJ, Lee YS, et al. Lipiodol solution of a lipophilic agent, 188-Re-TDD, for the treatment of liver cancer. Nucl Med Biol. 2001;28:197-204.
14. 188Re-labelled long chain alkyl diaminedithiol for therapy of liver cancer. Nucl Med Commun. 2002;23:237-242.
15. Sundram FX, Jeong JM, Zanzonico P, et al. Trans-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: an IAEA sponsored multi-centre phase 1 study. World J Nucl Med. 2002;1:5-11.
16. Sundram F, Chau TC, Onkhuudai P, et al. Preliminary results of transarterial rhenium-188 HDD lipiodol in the treatment of inoperable primary hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:250-257.
17. Guhlke S, Beets AL, Oetjen K, et al. Simple new method for effective concentration of Re-188 solutions from alumina-based W-188-Rc-188 generator. J Nucl Med. 2000;4:1271-1278.
18. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 1996;37:538-546.
19. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34:689-694.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216.
21. 131I-lipiodol therapy in patients with hepatocellular carcinoma. J Nucl Med. 2004;45:612-618.
22. Steel GG. The dose-rate effect: brachytherapy. In: Steel GG, ed. Basic Clinical Radiobiology. London, U.K.: Edward Arnold Publishers; 1993:120-129.
23. 131I-lipiodol delivery on tumour uptake and response. Nucl Med Commun. 2003;24:391-396.
24. Raoul JL, Bourguet P, Bretagne JF, et al. Hepatic artery injection of I-131 -labeled lipiodol: biodistribution study results in patients with hepatocellular carcinoma and liver metastases. Radiology. 1988;168:541-545.
25. Nakajo M, Kobayashi H, Shimabukuro K, et al. Biodistribution and in vivo kinetics of iodine-131 lipiodol infused via the hepatic artery of patients with hepatic cancer. J Nucl Med. 1988;29:1066-1077.
26. Madsen MT, Park CH, Thakur ML. Dosimetry of iodine-131 ethiodol in the treatment of hepatoma. J Nucl Med. 1988;29:1038-1044.
27. Monsieurs M, Bacher K, Brans B, et al. Patient dosimetry for 131-I-lipiodol therapy. Eur J Nucl Med Mol Imaging. 2003;30:554-561.